Skip to main content
Multiple Sclerosis Discovery Forum
User Top Menu
Who We Are
How to Cite
News & Future Directions
Essays & Opinions
Meetings & Events
Clinical Trials - Public Availability of Results
MS trials baseline
Map of MS Prevalence
Progressive MS Authors Galaxy
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Scientific Literature TreeMap
Clinical Trials in MS
Click Here to Support MSDF
You are here
Most Viewed Papers
Multiple sclerosis review.
The Long-Term Value of Glatiramer Acetate for the Treatment of Relapsing Remitting Multiple Sclerosis in the Netherlands.
Breastfeeding and multiple sclerosis relapses: a meta-analysis.
A Study of Efficacy and Safety of Ocrelizumab in Patients with Relapse-Remitting Multiple Sclerosis
A Multimodal Intervention for Patients with Secondary Progressive Multiple Sclerosis: Feasibility and Effect on Fatigue.
CellCept (Product Insert)
Mycophenolate Mofetil as a Monotherapy in Multiple Sclerosis: a multicentre retrospective study on 361 patients
Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.
Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis.
The differential diagnosis of neurological diseases by fractionating electrophoretically the CSF gamma-globulins.
RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation.
Myelin Sheath Development in the Maxillary Nerve of the Newborn Pig.
Genetics and the environment converge to dysregulate N-glycosylation in multiple sclerosis.
Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination.
Pathogenic implications of iron accumulation in multiple sclerosis.
Systematic Review of the Economics of Multiple Sclerosis in Latin America.
Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.
Level of education and multiple sclerosis risk over a 50-year period: Registry-based sibling study.
Comparison of Antibodies with Amylase Activity from Cerebrospinal Fluid and Serum of Patients with Multiple Sclerosis.
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
Tbet or Continued RORγt Expression Is Not Required for Th17-Associated Immunopathology.
Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients.
The effect of vitamin D-related interventions on multiple sclerosis relapses: a meta-analysis.
Reduction of CD8+ T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate
Immunosuppressive properties of mesenchymal stem cells: advances and applications.